Prescription drug · ANDA
Bumetanide NDC 68462-469
Bumetanide .25 mg/mL · Injection · Intramuscular, Intravenous · GLENMARK PHARMACEUTICALS INC., USA
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68462-469-54 | 68462046954 | 10 VIAL, SINGLE-DOSE in 1 CARTON (68462-469-54) / 4 mL in 1 VIAL, SINGLE-DOSE (68462-469-40)Marketed from Jan 1, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Bumetanide
- Generic name (nonproprietary)
- bumetanide
- Active ingredients
- Bumetanide — .25 mg/mL
- Dosage form
- Injection
- Route
- Intramuscular, Intravenous
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 216434
- Marketing start
- Listing expires
- Other FDA classes
- Increased Diuresis at Loop of Henle (Physiologic effect)
- Identifiers
- Product ID 68462-469_f211e18e-2cd7-4316-8edc-089ed734ccb8SPL ID f211e18e-2cd7-4316-8edc-089ed734ccb8SPL set ID 680563fe-5d3a-49bc-86a5-740bda2acebeRxCUI 282486, 1727569UNII 0Y2S3XUQ5HUPC 0368462470541, 0368462469545
- Pharmacologic class
- Loop Diuretic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N468462046954followed by a unit qualifier and the quantityPackage 68462-0469-54. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Bumetanide Injection is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 216434
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | Fresenius Kabi USA, LLC | 65219-570 |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | Gland Pharma Limited | 68083-496 |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | Fresenius Kabi USA, LLC | 65219-572 |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | Gland Pharma Limited | 68083-497 |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | GLENMARK PHARMACEUTICALS INC., USA | 68462-470 |